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Aims Aim of this study was to compare a minimally fluoroscopic radiofrequency catheter ablation with conventional fluor-
oscopy-guided ablation for supraventricular tachycardias (SVTs) in terms of ionizing radiation exposure for patient and
operator and to estimate patients’ lifetime attributable risks associated with such exposure.
Methods and
results
We performed a prospective, multicentre, randomized controlled trial in six electrophysiology (EP) laboratories in
Italy. A total of 262 patients undergoing EP studies for SVT were randomized to perform a minimally fluoroscopic ap-
proach (MFA) procedurewith the EnSiteTMNavXTM navigation system or a conventional approach (ConvA) procedure.
The MFA was associated with a significant reduction in patients’ radiation dose (0 mSv, iqr 0–0.08 vs. 8.87 mSv, iqr
3.67–22.01; P, 0.00001), total fluoroscopy time (0 s, iqr 0–12 vs. 859 s, iqr 545–1346; P, 0.00001), and operator
radiation dose (1.55 vs. 25.33 mS per procedure; P, 0.001). In the MFA group, X-ray was not used at all in 72% (96/
134) of cases. The acute success and complication rates were not different between the two groups (P ¼ ns). The re-
duction in patients’ exposure shows a 96% reduction in the estimated risks of cancer incidence and mortality and an
important reduction in estimated years of life lost and years of life affected. Based on economic considerations, the
benefits of MFA for patients and professionals are likely to justify its additional costs.
Conclusion This is the first multicentre randomized trial showing that a MFA in the ablation of SVTs dramatically reduces patients’
exposure, risks of cancer incidence and mortality, and years of life affected and lost, keeping safety and efficacy.
Trial registration clinicaltrials.gov Identifier: NCT01132274.
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What’s new?
† The radiation exposure during electrophysiology procedures
is non-negligible for both patients and laboratory staff.
† The use of a minimally fluoroscopic approach (MFA) with the
EnSiteTMNavXTM navigation system is associated with a
significant reduction in total fluoroscopy time, patients’ ex-
posure, and operator radiation dose without any significant
difference in terms of success and complication rates. The
reduction in patients’ exposure shows a 96% reduction in
the estimated risks of cancer incidence and mortality and
an important reduction in estimated years of life lost and
years of life affected.
† The increase in life expectancy and in the period of cancer-
free life makes the MFA economically affordable at a rough
economical analysis. Thus, faced with such an advantage in
terms of cancer prevention, it would be desirable that MFA
procedures were increasingly performed, at least in young
patients.
Introduction
Electrophysiology (EP) procedures are traditionally performed
under fluoroscopic guidance and often involve a non-negligible
radiation exposure1–4 for both patients and laboratory staff.
Fluoroscopy is certainly a highly effective way to navigate cathe-
ters and to monitor their location; unfortunately, fluoroscopy
requires the administration of ionizing radiation, and recent epi-
demiological evidence shows that even low doses can be harmful
and that no completely safe dose exists.4
In the past two decades, non-fluoroscopic three-dimensional
(3D) mapping systems have been used in complex arrhythmias
ablation to guide the ablation strategy. More recently, non-
fluoroscopic 3D mapping systems have been broadly investigated
for the complete or near-complete abolishment of radiation expos-
ure during ablation procedures, both in paediatric patients5–12 and
in adults,13–21 showing that catheter ablation through a minimally
fluoroscopic approach (MFA) is feasible and safe. However, most
of the data come from monocentric, non-randomized, feasibility
studies. Therefore, it remains unclear whether such an approach
results in a clinically significant reduction in exposure to ionizing
radiation for both patient and operator.
The multicentre, randomized controlled NO-PARTY trial (www.
clinicaltrials.gov identifier NCT01132274) has been designed to
compare a minimally fluoroscopic radiofrequency catheter ablation
(RFCA) guided by the EnSiteTMNavXTM navigation system with
conventional fluoroscopy-guided RFCA for supraventricular tachy-
cardias (SVTs) in terms of ionizing radiation exposure for both
patient and operator and to estimate patients’ lifetime attributable
risks (LAR) associated with such exposure.
Methods
An investigator-initiated, multicentre, randomized controlled trial was
performed in six Italian EP laboratories. Randomization of participants
occurred between January 2010 and February 2013; follow-up was
completed in March 2014. The complete study protocol has been pre-
viously described22 (see Supplementary material online). Written
informed consent was obtained from all participants. The trial was
approved by each institutional review board.
Patients aged 14–50 years undergoing SVTs RFCAwere randomized
on a 1 to 1 ratio to perform an EP procedure with a MFA or convention-
al approach (ConvA). In case of a MFA procedure, the EnSiteTMNavXTM
system was used as the primary catheter visualization tool (Figure 1) and
procedures were performed only by MFA-skilled operators.23–26 Any-
way, the use of fluoroscopy was allowed in case the operator would
have considered it necessary.
For both groups, fluoroscopic units were optimized at lower-
exposure settings; in Supplementary material online, Table S1, charac-
teristics of radiographic/fluoroscopic units are described.
For all patients, total procedural time, time necessary to position
catheters, EP study time, and cumulative radiofrequency delivery time
were collected.
Ionizing radiation use was calculated as total fluoroscopy time;
patient’s radiation exposure was measured in terms of dose-area prod-
uct (DAP), while operator exposure was analysed with a specific kit of
radiation dosimeters.
A follow-up outpatient visit was scheduled for each patient at 1, 3, 6,
and 12 months to take an updated history, perform physical examin-
ation, and obtain a 12-lead electrocardiogram.
Endpoints
The primary endpoint of the study was the reduction in the total radi-
ation dose to the patient. Secondary endpoints were procedural suc-
cess, reduction in the procedural fluoroscopy time, and reduction in
the operator radiation dose. Moreover, an economic assessment has
been performed to evaluate the additional costs associated with a
MFA approach.
Radiation dose analysis
For each fluoroscopy, the interactions between the X-ray beam and the
patient were simulated via Monte Carlo calculation based on the geom-
etry field of the procedure using the validated software PCXMC version
2.0.27 The X-ray spectra were reconstructed from the X-ray tube
settings (tube potential, anode angle, filtration) according to Birch and
Marshall theory,28 and a modified Cristy and Eckerman mathematical
hermaphrodite phantom was used to represent a digital phantom
shaped on patient’s height, weight, and age. Finally, measurements of
DAP were converted into organ doses, and effective doses (EDs)
were estimated for each projection using the ICRP 103 weighing factor.
Effective dose was also calculated with the accepted formula: mSv ¼
DAP (Gy cm2) × 0.20 to better compare our data with others
published.29
The risk of late effects induced by ionizing radiation exposure was
assessed in terms of LAR from equivalent organ doses calculated with
the Monte Carlo code, according to the Biological Effects of Ionizing
Radiation (BEIR) empirical risk models. Years of life lost (YLL) and years
of life affected (YLA) were determined with the same risk model.30
Finally, starting from the YLL and YLA, a rough economic analysis has
been performed using the Health Technology Assessment.31
The ED to the first operator was assessed from data collected by
lithium–fluoride thermoluminescent dosimeters (TLD) positioned on
chest. The cumulative dose was measured over consecutive procedures
to achieve better accuracy and avoid underestimation due to the small
exposure per procedure. Different dosimeter sets were used during
ConvA and MFA procedures. Dosimeters were replaced every
2 months.
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Figure 1 (A) Non-fluoroscopic three-view reconstruction of the right atrium in right anterior oblique (on the left) and in left anterior oblique
(on the right) views. The cloud of green points shows the sites reached by the mapping catheters and used for geometry reconstruction. (B) The
same geometry showing catheter position inside the atrium: yellow catheter in coronary sinus, blue catheter in Hisian region, and white ablation
cathetermapping Koch triangle. Themapping system allows tomark the areas of interest: in this case, wemarked where ablation pulses were safely
and effectively delivered as shown in the intracavitary electrograms recording box (bottom).
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Statistical analysis
Descriptive statistic has been reported as mean+ standard deviation or
median and interquartile Q1–Q3 range (iqr) for skewed distributions in
the case of continuous variables and as absolute frequencies and per-
centages in the case of categorical variables. Between-groups compari-
son has been performed with the unpaired Student’s t-test, the Mann–
Whitney U test, or Fisher’s exact test. Statistical differences in ED and
fluoroscopy time between groups were tested with the independent
Mann–Whitney U test (95% confidence level). All tests are two sided,
and a P-value of ,0.05 has been considered statistically significant. All
statistical analyses were performed with the SPSS 21.0 software.
Results
Patients’ enrolment in the study is depicted in Figure 2.
Of the 262 participants (110 males, mean age 35.8+10.4 years),
134 (51%) were assigned to MFA group and 128 (49%) to ConvA
group. The clinical characteristics of the two groups were compar-
able (Table 1).
Procedural features
Of the 262 enrolled patients, 231 (88%) underwent an ablation fol-
lowing the EP study. Supplementary material online, Results section
and Table S2, summarizes procedural data.
A 99% acute success rate was achieved in both groups (P ¼ ns)
with a complications rate of 1.1% (P ¼ ns). The procedural
complications were as follows: one arteriovenous fistula solved by
compression in MFA group and two first-degree atrioventricular
node blocks spontaneously solved in 48 h in ConvA group. The
mean follow-up time was 12+ 4 months, during which no
procedure-related complication occurred. Of the 231 patients who
underwent an ablation, the long-term success rate was 97% in MFA
group and 94% in ConvA group (P ¼ ns).
Fluoroscopy use and effective dose
Fluoroscopy time and patient ED were significantly lower in the
MFA group (0 s, iqr 0–12; 0 mSv, iqr 0–0.08) when compared
with ConvA group (859 s, iqr 545–1346; 8.87 mSv, iqr 3.67–
22.01; P, 0.00001). Similar results were obtained when the ana-
lyses were restricted to the 231 procedures that ended with an
ablation.
In the MFA group, X-ray was not used at all throughout the pro-
cedure in 72% (96/134) of cases.
Table 2 and Supplementary material online, Results section, de-
scribe fluoroscopy data.
Lifetime attributable cancer risk
LAR estimates are reported in Table 3 and Supplementary material
online, Results section and Tables S3–S8.
The risks of cancer incidence and mortality from a MFA proced-
ure were reduced by 96% compared with ConvA procedure. As
279 patients undergoing RF catheter ablation of SVT
Assessed for elegibility
262 Randomized
Conventional approach
N = 128
EP study only: 15 (12%)
EP study + ablation: 113 (88%)
128 pts in primary analysis
Minimally fluoroscopic approach
N = 134
EP study only: 16 (12%)
EP study + ablation: 118 (88%)
134 pts in primary analysis
Clinical follow-up in 231 RF ablation pts
106 pts: 1 month fu
102 pts: 3 months fu
99 pts: 6 months fu
90 pts: 1 year fu
7 pts lost at fu
116 pts: 1 month fu
107 pts: 3 months fu
102 pts: 6 months fu
88 pts: 1 year fu
2 pts lost at fu
n = 2 pts
Figure 2 Study flowchart showing enrolment, randomization and follow-up of participants. In two cases, the MFA procedure was shifted to a
ConvA one because of first operator change in one case and mapping system failure in the other one. Both these procedures were included in the
MFA group as an intention-to-treat analysis.
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expected, all risks decreased with aging and were always higher for
female patients at the same age of intervention.
Furthermore, a dramatic reduction has been calculated in YLL
and YLA in MFA group in comparison with ConvA group (Table 4).
Undergoing a ConvA EP procedure at 35 years of age results in
almost 1 week of ‘life-lost’ and in about 2 weeks of ‘life-affected’
per patient, in contrast with 5 h and half a day, respectively, with
the MFA approach.
Economic considerations
The significant reduction in YLL and YLA observed with the MFA
could also be seen as an increase in life expectancy and in the period
of life without cancer. Assuming that the period of life with cancer
halves optimal quality of life, it can be derived that each patient gains
2 adjusted quality of life weeks, e.g. 0.0348 quality-adjusted life years.
Using a range for the cost-effectiveness threshold between 30 000
and 50 000 as suggested in some jurisdictions,32 the intervention
would be affordable for an additional net cost ranging between
E1151 and E1918. This cost is approximately equivalent to the ex-
tra cost deriving from the electroanatomic mapping system.
Ionizing radiation risk for
electrophysiology physicians
For EP physicians, the estimated cumulative EDs were calculated
taking into account the shielding correction for using the protective
apron and the thyroid collar and were obtained from the data col-
lected by a total number of 213 procedures (113MFA and 100 Con-
vA groups). As for patients, the ED was significantly lower in MFA
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Table 2 Ionizing radiation data
MFA ConvA P
All patients (n ¼ 262)
Fluoroscopy time (s) 0 [0–12] 859 [545–1346] ,0.00001
DAP (cGy cm2) 278 [80–791] 2036 [854–5297] ,0.00001
ED (mSv) 0 [0–0.08] 8.87 [3.67–22.01] ,0.00001
Extrapolated ED (mSv) 0 [0–0] 3.96 [1.68–10.54] ,0.00001
Fluoro on pelvic area, n (%) 3/134 (2) 62/128 (48) ,0.0001
Extrapolated ED: ED extrapolated by the formula: mSv ¼ DAP (Gy cm2) × 0.20.
ED, effective dose; DAP, dose-area product.
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Table 3 Lifetime attributable risks
LAR Age MFA ConvA
Man Woman Man Woman
Mortality 15 4.8 (2.5–8.2) 6.1 (3.9–9.2) 136 (82–215) 186 (131–265)
25 4.0 (1.8–7.0) 4.7 (2.8–7.4) 105 (59–171) 138 (94–200)
35 3.7 (1.6–6.7) 4.2 (2.4–6.7) 94 (51–156) 119 (79–175)
45 3.7 (1.5–6.9) 4.1 (2.3–6.7) 94 (49–158) 115 (76–171)
Incidence 15 11.0 (6.0–18.6) 15.4 (9.9–25.3) 321 (198–512) 486 (333–773)
25 8.4 (4.3–14.4) 10.9 (6.9–17.4) 236 (140–377) 335 (230–509)
35 7.4 (3.6–12.9) 8.9 (5.5–14.0) 201 (117–324) 267 (183–393)
45 7.3 (3.4–12.8) 8.2 (5.0–12.8) 195 (111–315) 241 (165–350)
Lifetime attributable risks of all cancers mortality and incidence, calculated according to BEIR risk models, with 95% confidence intervals from MFA (N ¼ 134) and ConvA
procedures (N ¼ 128) in function of age at exposure and sex (number of cases in 100.000).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Demographic characteristics
MFA
n 5 134
ConvA
n5 128
P
Female, n (%) 79 (59) 73 (57) ns
Age (years) 36.3+10.4 35.4+10.4 ns
BMI 24.4+4.4 23.5+4.4 ns
Previous ablation, n (%) 10 (8) 13 (10) ns
EPS, n (%) 16 (12) 15 (12) ns
AVNRT, n (%) 84 (63) 79 (62) ns
Right AP, n (%) 10 (8) 11 (9) ns
Left AP, n (%) 11 (8) 14 (11) ns
AFl, n (%) 10 (8) 6 (5) ns
AT, n (%) 3 (2) 3 (2) ns
BMI, body mass index; EPS, electrophysiological study; AVNRT, atrioventricular
node re-entry tachycardia; AP, accessory pathway; AFl, atrial flutter; AT, atrial
tachycardia.
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group (1.55 mSv per procedure) in comparison with ConvA group
(25.33 mSv per procedure; P, 0.001).
Discussion
Main findings of the study
This is the first prospective multicentre randomized study compar-
ing conventional fluoroscopy-guided procedures with procedures
performed using the electroanatomical mapping system as the pri-
mary catheter visualization tool in patients undergoing EP study
for SVTs. The results confirm safety and efficacy of a MFA in the ab-
lation of a wide range of SVTs. Notably, this randomized study
shows that MFA allows a significant reduction in patient’s exposure
and a decrease in the estimated risks of cancer incidence and mor-
tality and of YLA and YLL. Of course, the choice of MFA also affects
the ionizing radiation exposure of the medical staff.
Obviously, MFA involves a greater expense, but the benefits de-
riving from it are offset in terms of cancer prevention strategy, and,
based on our data, the increase in life expectancy makes it econom-
ically affordable in most European countries.
Radiological exposure and risks
Medical radiological exposure and risks are topical and emerging is-
sues of last year literature.33–36 Cardiologists are responsible for
40% of the entire ED from all medical sources, as a consequence
of new capabilities and widespread availability of new imaging tech-
niques that require X-rays.37 Radiation exposure involves patients
and operators, resulting in a non-negligible health risk for both.
A cornerstone to enhance radiation safety is optimization, i.e. re-
ducing as much as possible the use of X-rays for a given technique.26
Techniques that allow high-quality imaging with lower radiation ex-
posure should therefore be used when available.
In our study, we showed that the use of one of these techniques
(EnSiteTMNavXTM system) is effective in reducing radiation expos-
ure during EP procedures, with an identical success rate and without
significantly increasing procedural time.
Considering that X-rays are proven carcinogens (Class 1), the sig-
nificant increase in the cumulative exposure of patients and popula-
tion is likely to cause an increased incidence of cancer, with an
important yet potentially avoidable public health threat.27 This is
the only published study that estimates the lifetime attributable can-
cer risk of radiation with the Monte Carlo code. The use of MFA re-
duced LAR by 96%, particularly in the youngest patients and in
women. Also YLL and YLA were significantly reduced in the MFA
group. The difference between median EDs calculated with the
Monte Carlo code and with the international formula31 is probably
due to the characteristics of our study population, which is mainly
constituted by young and female patients. The advantage of the
use of the electroanatomic system was in any case statistically
significant.
Reduction in radiation exposure during medical procedures is
crucial also for the medical staff. The occupational radiation expos-
ure of cardiac electrophysiologists is two to three times higher than
that of diagnostic radiologists.27 Cardiac use of fluoroscopy almost
never reaches the threshold for deterministic radiation injury, but it
gives an additional lifetime risk of fatal and non-fatal cancers ranging
from 1/10 000 to 1/1000 that we should not underestimate. In our
study, we confirmed that performing MFA ablation of SVTs signifi-
cantly reduces professional exposure.
Economic considerations
The Health Technology Assessment evaluates medical technologies
under clinical, ethical, organizational, and economic points of view
to assess if they are worth being funded.38,39
The MFA clearly produces clinical benefits for both patients and
medical staff as it decreases the risk of cancer due to radiation ex-
posure. It may be argued that avoiding patients’ risks for unrelated
diseases and protecting medical staff in its professional environment
deserve a higher priority. From a strictly economic perspective, the
crucial issue is whether MFA in ablation is affordable given the con-
straints in available resources. This study does not provide enough
data to conduct a cost-effectiveness analysis, but it gives robust evi-
dence in terms of increase in life expectancy and in period of life free
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Table 4 Years of life lost and years of life affected
Age MFA ConvA
Man Woman Man Woman
YLL 15 0.00088 (0.00038–0.0016) 0.00112 (0.00065–0.00180) 0.023 (0.012–0.038) 0.032 (0.022–0.048)
25 0.00061 (0.00026–0.00112) 0.00079 (0.00046–0.00127) 0.016 (0.008–0.026) 0.023 (0.015–0.033)
35 0.00052 (0.00022–0.00095) 0.00065 (0.00037–0.00105) 0.013 (0.007–0.022) 0.018 (0.012–0.027)
45 0.00049 (0.00019–0.00090) 0.00059 (0.00033–0.00097) 0.012 (0.006–0.020) 0.017 (0.011–0.025)
YLA 15 0.0023 (0.0011–0.0042) 0.0037 (0.0022–0.0065) 0.063 (0.035–0.106) 0.113 (0.073–0.192)
25 0.0015 (0.0007–0.0027) 0.0023 (0.0014–0.0039) 0.042 (0.024–0.068) 0.071 (0.048–0.112)
35 0.0012 (0.0006–0.0021) 0.0017 (0.0010–0.0027) 0.032 (0.018–0.053) 0.051 (0.035–0.076)
45 0.0011 (0.0005–0.0019) 0.0014 (0.0008–0.0022) 0.029 (0.016–0.047) 0.040 (0.027–0.059)
Years of life lost and YLA with 95% confidence intervals from MFA (N ¼ 134) and ConvA procedures (N ¼ 128) in function of age at exposure and sex. Years of life lost are
estimated subtracting the effective years of life lived from the life expectancy for every patient who dies from cancer according to the LAR calculation and dividing it by the number
of subjects who underwent the procedure. It results in an estimation of YLL per patient. For example, performing a ConvA procedure on a woman aged 15 years means that this
womanwill live 11.68 days (0.032×365 days/year) less than expected. Translating it into a population of 1000 women aged 15 years, it means that the procedureswould account for
a total of 32 YLL (0.032×1000 subjects).
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from cancer. This means that MFA procedures might be considered
economically affordable in most European countries.
Procedural features
Considering technical and procedural aspects, the 3D electroana-
tomic system shows advantages not only as an efficient navigation
system but also as a mapping system, thus reducing X-ray exposure.
For example, a precise definition of the anatomy of the triangle of
Koch and of the His bundle (which is visualized as an area rather
than just a point) facilitates atrioventricular node re-entry tachycar-
dia (AVNRT) ablation and avoids the need for continuously moni-
toring with fluoroscopy the exact position of the node.
Furthermore, the 3D electroanatomic system overcomes the diffi-
culties deriving from the disappearance of pre-excitation after the
initial radiofrequency pulses, and it makes it easier to accurately re-
localize the accessory pathway (AP), thus avoiding time- and
radiation-consuming electrophysiological manoeuvres. Moreover,
thanks to the possibility of creating an activation map, it permits
to eventually localize the gap in case of an incomplete line during at-
rial flutter ablation. Finally, it allows greater catheter stability in every
kind of procedures, as demonstrated by fewer but longer radiofre-
quency pulses observed in our MFA group.
As a consequence of all these advantages, we believe that specific
training in the ‘minimal fluoroscopic approach’ should be part of
every EP education programme.
Study limitations
The main limitation of our study is that the relationship between the
ED and its lifetime attributable risk was developed according to
internationally accepted empirical risk models,29 and it could be cri-
ticized that these models are not recommended for estimating risks
in individual patients. Nevertheless, it must be emphasized that no
epidemiological study exists about low levels of ionizing radiation
and we regret that no biomarkers of acute ionizing radiation injury
were investigated.
We acknowledge that we did not perform an analysis about the
dose for allied professionals involved in the procedures and that we
did not estimate the lifetime risks for operators and allied profes-
sionals. These matters should be properly evaluated by a specifically
designed trial.
Furthermore, both ConvA andMFA procedures were performed
differently in various EP labs (i.e. numbers of diagnostic catheters,
strategy in ablating left APs, etc.), but in the study protocol, we in-
tentionally decided to allow the operators working as routinary as
possible to have a better snapshot of MFA in everyday live EP labs.
Finally, a more exhaustive cost-effectiveness analysis would be
desirable. The economic observations reported suggest a first point
of reference about the additional costs for which the undiscounted
gain benefits for patients might be considered affordable in Euro-
pean countries, although crucial elements that may largely affect
the overall value for money are missing.
Conclusion
The NO-PARTY study is the first multicentre randomized con-
trolled trial confirming that MFA in SVTs ablation results in a clinic-
ally significant reduction in exposure to ionizing radiation for both
patient and operator. Notably, the reduction in patients’ exposure
achieves a dramatic reduction in the estimated risks of cancer inci-
dence and mortality and in YLA and YLL. The increase in life expect-
ancy and in the period of cancer-free life makes the MFA
economically affordable at a rough economical analysis. Thus, faced
with such an advantage in terms of cancer prevention, it would be
desirable that MFA procedures were increasingly performed, at
least in young patients.
Supplementary material
Supplementary material is available at Europace online.
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